Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Population Pharmacokinetics of Cyclosporine after Hematopoietic Stem Cell Transplantation in Leukemic Patients

조혈모세포이식을 받은 한국 성인 백혈병환자에서 cyclosporine의 집단약동학 분석

  • Kim, Seung-Hee (College of Pharmacy, Seoul National University) ;
  • Kim, Kyung-Im (College of Pharmacy, Seoul National University) ;
  • Yun, Hwi-yeol (Drug Discovery Laboratory, Choongwae Pharma Corporation) ;
  • Kang, Won-Ku (College of Pharmacy, Catholic University of Daegu) ;
  • Yoon, Sung-Soo (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Shin, Wan-Gyoon (College of Pharmacy, Seoul National University) ;
  • Lee, Hye-Suk (Department of Pharmacy, Seoul National University Hospital) ;
  • Oh, Jung-Mi (College of Pharmacy, Seoul National University)
  • Received : 2010.03.17
  • Accepted : 2010.04.12
  • Published : 2010.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: 본 연구는 한국인 성인 조혈모세포이식환자를 대상으로 경구용 사이클로스포린의 집단약동학 분석을 통하여 사이클로스포린의 약동학적 파라미터에 영향을 미치는 요인 분석을 실시하고자 하였다. Methods: 2000년 12월부터 2006년 8월까지 서울대학교병원에서 동종조혈모세포이식을 받고 면역억제제로 사이클로스포린을 복용한 성인 백혈병환자를 대상으로 후향적으로 자료를 수집하였다. 사이클로스포린의 약동학에 영향을 미치는 인자로는 연령, 성별, 이식 후 날짜, 신기능, 공여자와의 관계, 질병의 종류, 혈중 빌리루빈 농도, 사이클로스포린의 대사를 유도하는 프레드니솔론의 투여량, 헤마토크리트, 사이클로스포린의 대사를 저해하는 약물의 병용여부 등을 검토하였다. 분석은 NONMEM$^{(R)}$ VI 프로그램을 이용하였으며, 변수를 추가하지 않은 기본 모형을 만든 후에 단계적인 요인의 추가와 제거를 통해 최종모형을 제작하였다. Results: 최종 상관 모형은 다음과 같다; CL/F (L/h) = $85.6{\times}e^{(0.646\;{\times}\;HCT/28.9\;+\;0.0464\;{\times}\;Gender)}$. 사이클로스포린의 겉보기 클리어런스는 환자의 성별이 남자일 때 또는 헤마토크릿이 감소할수록 증가하였다. 그 외 파라미터는 다음과 같이 계산되었다; $K_{\alpha}=0.0787\;(h^{-1})$; Q=57.1(L/kg/h); $V_{d-central\;compartment}$=1,100 (L); $V_{d-peripheral\;compartment}$ = 213,000(L). 개체간 편차는 40% 미만이었으며, 개체내 편차를 포함하는 잔차는 24.02%였다. Conclusions: 사이클로스포린의 약동학적 특징과 그 클리어런스에 영향을 끼칠 수 있는 임상적 요인을 이해하는 것은 환자 개개인의 용량과 용법의 결정 및 이상반응 발생의 예방에 유용할 수 있다. 한국인 조혈모세포이식환자에서 사이클로스포린의 약동학에 영향을 미치는 최종 파라미터를 구한 본 연구의 결과는 조혈모세포이식을 받은 한국인 성인환자에서 사이클로스포린의 모니터링 및 용량조절에 유용할 것으로 전망된다.

Keywords

References

  1. Miller KB, Schenkein DP, Comenzo R, et al., Adjusteddose continuous-infusion cyclosporin A to prevent graftversus- host disease following allogeneic bone marrow transplantation. Ann Hematol. 1994; 68: 15-20. https://doi.org/10.1007/BF01695914
  2. Gondo H, Harde M, Taniguchi S, et al., Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease. Bone Marrow Transplant. 1993; 2: 437-441.
  3. Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem. 2001; 34(1): 9-16. https://doi.org/10.1016/S0009-9120(00)00175-2
  4. Abendroth D. Experience with therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004; 36(2 Suppl): 426S-429S. https://doi.org/10.1016/j.transproceed.2003.12.024
  5. Kasiske BL, Heim-Duthoy K, Rao KV, et al., The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation. 1988 Nov; 46(5): 716-722. https://doi.org/10.1097/00007890-198811000-00017
  6. Yee GC, Self SG, McGuire TR, et al., Serum cyclosporine concentration and risk of acute graft-versushost disease after allogeneic marrow transplantation. N Engl J Med. 1988; 319:65-70. https://doi.org/10.1056/NEJM198807143190201
  7. Parkman R. Cyclosporine: GVHD and beyond. N Engl J Med. 1988; 319: 110-111. https://doi.org/10.1056/NEJM198807143190209
  8. Przepiorka D, Shapiro S, Schwinghammer TL, et al., Cyclosporine and methylprednisolone after allogeneic marrow transplantation: Association between low cyclosporine concentration and risk of acute graft-versushost disease. Bone Marrow Transplant. 1991; 7: 461-465.
  9. Schmidt H, Ehninger G, Dopfer R, et al., Correlation between low CSA plasma concentration and severity of acute GvHD in bone marrow transplantation. Blut. 1988; 57: 139-142. https://doi.org/10.1007/BF00320154
  10. Kennedy MS, Yee GC, McGuire TR, et al., Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients. Transplantation. 1985; 40: 249- 253. https://doi.org/10.1097/00007890-198509000-00005
  11. Lindholm A, Ringden O, Lonnqvist B. The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients. Transplantation. 1987; 43: 680-684. https://doi.org/10.1097/00007890-198705000-00016
  12. Beal L, SL. NONMEM User Guide. 1992, San Francisco, CA: NONMEM Project Group, UCSF.
  13. Yee GC, McGuire TR, Gmur DJ, et al., Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation Influence of age, obesity, and hematocrit. Transplantation.1988; 46: 399-402. https://doi.org/10.1097/00007890-198809000-00012
  14. Schultz KR, Nevill TJ, Joze CL, et al., The pharmacokinetics of oral cyclosporin A (Neoral) during the first month after bone marrow transplantation. Transplant Proc. 1998; 30: 1668-1670. https://doi.org/10.1016/S0041-1345(98)00385-6
  15. Rui JZ, Zhuo HT, Jiang GH, et al., Evaluation of population pharmacokinetics of cyclosporin A in renal transplantation patients with NONMEM, Yao Xue Xue Bao. 1995; 30(4): 241-247.
  16. Shibata N, Hayakawa T, Hoshino N, et al., A predictive model for area under the concentration versus time curve of cyclosporin A using several routine monitoring results in renal transplant patients. Biol Pharm Bull. 1997; 20(8): 897-903. https://doi.org/10.1248/bpb.20.897
  17. Min DI, Lee M, Ku YM, et al., Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther 2000 Nov; 68(5): 478-486. https://doi.org/10.1067/mcp.2000.111255
  18. Molpeceres J, Chacon M, Guzman M, et al., Dependency of cyclosporine tissue distribution and metabolism on the age and gender of rats after a single intravenous dose. Int J Pharm. 2000 Mar 20; 197(1-2): 129-141. https://doi.org/10.1016/S0378-5173(99)00461-5
  19. Jacobson PA, Fuki NG, Kathlenn GE, et al., Posttansplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation. Biology of blood and marrow transplantation 2003: 9: 304-311. https://doi.org/10.1016/S1083-8791(03)00076-4
  20. Wu KH, Cui YM, Guo JF, et al., Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos. 2005; 33(9): 1268-1275. https://doi.org/10.1124/dmd.105.004358
  21. Charpiat, Bruno, Falconi, et al., A Population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with bayesian fitting. Ther Drug Monit. 1998; 20(2): 158-164. https://doi.org/10.1097/00007691-199804000-00005
  22. Rosenbaum SE, Baheti G, Trull AK, et al., Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit. 2005; 27(2): 116-122. https://doi.org/10.1097/01.ftd.0000148448.51225.2c
  23. Yee GC, Kennedy MS, Storb R, et al., Effect of hepatic dysfunction on oral cyclosporin pharmacokinetics in marrow transplant patients. Blood. 1984; 64: 1277-1279.
  24. Kahan BD, Kramer WG, Wideman C, et al., Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation. 1986; 41: 459-464. https://doi.org/10.1097/00007890-198604000-00009
  25. Moyer TP, Johnson P, Faynor SM, et al., Cyclosporine: A review of drug monitoring problems and presentation of a simple, accurate liquid chromatographic procedure that solves these problems. Clin Biochem. 1986; 19: 83-89. https://doi.org/10.1016/S0009-9120(86)80053-4
  26. Donatsch P, Abisch E, Homberger M, et al., A radioimmunoassay to measure cyclosporin A in plasma and serum samples. J Immunoassay. 1981; 2: 19-32. https://doi.org/10.1080/01971528108062989
  27. McLachlan AJ, Tett SE. Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach.Ther Drug Monit. 1998; 20: 390-395. https://doi.org/10.1097/00007691-199808000-00007
  28. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Part I). Clin Pharmacokinet. 1990; 19: 319-332. https://doi.org/10.2165/00003088-199019040-00004
  29. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Part II). Clin Pharmacokinet. 1990; 19: 400-415. https://doi.org/10.2165/00003088-199019050-00004
  30. Yates CR, Zhang W, Song P, et al., The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 2003; 43(6): 555-564. https://doi.org/10.1177/0091270003253617
  31. Pichard L, Fabre I, Fabre G, et al., Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos. 1990; 18(5): 595-606.
  32. Jones TE, Morris RG, Mathew TH. Diltiazem-cyclosporin pharmacokinetic interaction--dose-response relationship. Br J Clin Pharmacol. 1997; 44(5): 499-504.